Trending Now

Important medical research and remarkable case reports worth knowing.

Selected from high-relevance medical literature published in the last 14 days.

AllClinical ResearchCase Reports
FeaturedClinical ResearchPreventive Medicine / Public Health

2025 National Guidelines on the Mediterranean Diet: Executive Summary of a Joint Report by Italian Scientific Societies and the National Institute of Health Task Force on Clinical Practice Guidelines.

Nutr RevNov 12, 2026

This systematic review and practice guideline, developed by a multidisciplinary panel using NUTRIGRADE, assessed Mediterranean diet evidence across nine health domains and one economic domain.

Why it matters

The guideline synthesizes evidence across multiple clinical and public health domains, indicating that dietary patterns may be relevant to prevention and outcomes across a broad range of non-communicable diseases.

Read summary

Also worth knowing

Clinical ResearchOncology (Medical)

Poly (ADP-ribose) polymerase inhibitors (PARPi) for treating advanced epithelial ovarian cancer.

This Cochrane systematic review and meta-analysis assessed randomised trials of PARP inhibitors (PARPi) in women with newly diagnosed or recurrent epithelial ovarian cancer. It included 24 studies with 8961 participants.

Cochrane Database Syst RevNov 11, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Postoperative Tumor-Informed Circulating Tumor DNA Status for Molecular Residual Disease Detection After Curative-Intent Resection of Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis pooled observational evidence on postoperative tumor-informed circulating tumor DNA (ctDNA) as a marker of molecular residual disease after curative-intent resection of…

J Gastrointest CancerNov 11, 2026Read summary
Clinical ResearchOncology (Medical)

Primary Endocrine Therapy vs Upfront Surgery for Older Women With Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-Analysis.

This systematic review and meta-analysis compared primary endocrine therapy (pET) with upfront surgery for operable, nonmetastatic, estrogen receptor-positive breast cancer in older women.

JAMA Netw OpenNov 2, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Dose-dense neoadjuvant bi-weekly nab-paclitaxel followed by epirubicin-cyclophosphamide versus bi-weekly docetaxel followed by epirubicin-cyclophosphamide in patients with HR+/HER2- early breast cancer: a multicentre, randomised, phase III trial.

This multicentre, randomised phase III trial at three hospitals in China compared dose-dense neoadjuvant nab-paclitaxel with docetaxel, each followed by epirubicin-cyclophosphamide, in patients with early HR+/HER2−…

Breast Cancer Res TreatNov 9, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Pertuzumab in HER2-positive breast cancer: a systematic review and meta-analysis of randomized controlled trials.

This systematic review and meta-analysis pooled 8 randomized controlled trials involving 8367 patients with HER2-positive breast cancer to assess pertuzumab-based regimens.

Breast Cancer Res TreatNov 9, 2026Read summary
Clinical ResearchCardiologyOpen access

Specialist Referral for Cardiovascular Risk in Patients With Prostate Cancer: A Randomized Clinical Trial.

This multicenter randomized clinical trial tested whether routine cardiovascular-specialist referral improved risk-factor control and cardiovascular outcomes in patients with prostate cancer who were starting or had…

JAMA Intern MedNov 1, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Prophylactic dexamethasone for prevention of opioid-induced nausea and vomiting in cancer patients: a randomised controlled trial (DEX-OINV Trial).

This open-label randomised controlled trial at a tertiary cancer centre evaluated prophylactic oral dexamethasone in opioid-naïve adults with cancer starting oral morphine.

Support Care CancerNov 7, 2026Read summary
Clinical ResearchOncology (Medical)Open access

Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve ALK -Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.

DIAMOND-2 was a multicenter, randomized, open-label phase III trial comparing dirozalkib with crizotinib in adults with ALK inhibitor-naïve, ALK-positive advanced non-small-cell lung cancer.

Cancer Commun (Lond)Nov 10, 2026Read summary
Clinical ResearchHematology

Decitabine plus busulfan-cyclophosphamide versus busulfan-cyclophosphamide myeloablative conditioning before allogeneic haematopoietic stem cell transplantation for reducing risk of relapse in adult KMT2A‑rearranged leukaemia in China: an open-label, multicentre, randomised phase 3 trial.

This open-label, multicentre, randomised phase 3 trial compared decitabine plus busulfan-cyclophosphamide (DAC-BuCy) with BuCy conditioning before allogeneic HSCT in 130 patients aged 14–65 years with KMT2A-rearranged…

Lancet HaematolOct 30, 2026Read summary
Clinical ResearchHematology

Combining quizartinib with intensive chemotherapy for older patients with newly diagnosed AML: results of the UK NCRI AML18 trial.

The multicentre randomised UK NCRI AML18 trial evaluated quizartinib after intensive chemotherapy, with or without maintenance, in patients older than 60 years with newly diagnosed AML or high-risk myelodysplastic…

BloodNov 5, 2026Read summary
Clinical ResearchOncology (Medical)

Comparative efficacy and safety of second- and later-line BRAF-targeted regimens in BRAF V600E-mutant metastatic colorectal cancer: A systematic review and network meta-analysis.

This systematic review and network meta-analysis compared the efficacy and safety of second- and later-line BRAF-targeted regimens in adults with BRAF V600E-mutant metastatic colorectal cancer.

Medicine (Baltimore)Nov 6, 2026Read summary

Showing 12 of 124 publications that cleared our clinical screen in the last 14 days.

Looking for an earlier article?Everything that has appeared in Trending is in the archive.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.